Company
Theravance Biopharma
Theravance Biopharma has 24 drugs tracked on RxWires: 1 post-market, 1 in Phase 3, 1 in Phase 2/3, 8 in Phase 2, 13 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Revefenacin | Post-Market | Chronic Obstructive Pulmonary Disease |
| Ampreloxetine | Phase 3 | Symptomatic Neurogenic Orthostatic Hypotension |
| TD-1473 Dose A | Phase 2/3 | Ulcerative Colitis (UC) |
| TD-0903 | Phase 2 | Acute Lung Injury (ALI) Associated With COVID-19 |
| velusetrag dose 1 | Phase 2 | Gastroparesis |
| TD-5108 | Phase 2 | Chronic Constipation |
| Revefenacin Inhalation Solution [Yupelri] | Phase 2 | COPD |
| TD-8236 | Phase 2 | Asthma |
| TD-9855 | Phase 2 | Neurogenic Orthostatic Hypotension |
| 400 microgrammes GSK961081 | Phase 2 | Pulmonary Disease, Chronic Obstructive |
| Telavancin | Phase 2 | Infection |
| TD-1473 [Tablet A] | Phase 1 | Intestinal Disorder |
| TD-1607 | Phase 1 | Serious Infections Due to Known or Suspected Gram-positive Pathogens |
| GSK961081 15mcg SD | Phase 1 | Pulmonary Disease, Chronic Obstructive |
| TD-1473 for SAD | Phase 1 | Healthy |
| TD-1473 oral capsule | Phase 1 | Intestinal Disorders |
| TD-5202 | Phase 1 | Healthy |
| Ampreloxetine <Dose A> | Phase 1 | Symptomatic Neurogenic Orthostatic Hypertension |
| [14C]-GSK961081 solution for IV infusion | Phase 1 | Pulmonary Disease, Chronic Obstructive |
| TD-3504 | Phase 1 | Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects |
| TD-1439 | Phase 1 | Healthy Subjects |
| TD-1058 | Phase 1 | Idiopathic Pulmonary Fibrosis (IPF) |
| TD-6450 | Phase 1 | Hepatitis C |
| TD-0714 | Phase 1 | Healthy Adults, Elderly Subjects |
Latest
Follow Theravance Biopharma on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.